Last Updated: June 25, 2026

Bulk Pharmaceutical API Sources for CABOZANTINIB S-MALATE

✉ Email this page to a colleague

Bulk Pharmaceutical API Sources for CABOZANTINIB S-MALATE

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE	⤷ Start Trial	HY-12044	⤷ Start Trial
AbaChemScene	⤷ Start Trial	CS-0201	⤷ Start Trial
Chembase.cn	⤷ Start Trial	163523	⤷ Start Trial
Aurum Pharmatech LLC	⤷ Start Trial	W-5841	⤷ Start Trial
MolPort	⤷ Start Trial	MolPort-035-395-744	⤷ Start Trial
Axon Medchem	⤷ Start Trial	1819	⤷ Start Trial
Molepedia	⤷ Start Trial	M92116106P	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.